7/26/2025
Last update
7/26/2025
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 28 Researches
7.1
USERS' SCORE
Good
Based on 4 Reviews
8.4
Supplement Facts
Serving Size: 2 Soft Gels
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%
Saturated Fat
0 g
0%
Trans Fat
0 g
†
Vitamin D3 (cholecalciferol)
10 mcg (400 IU)
67%
Total Omega-3s♦
830 mg
†
EPA (Eicosapentaenoic Acid)
205 mg
†
DHA (Docosahexaenoic Acid)
480 mg
†
Top Medical Research Studies
8
We explored the connection between vitamin D levels and coronary thrombus load in patients who experienced ST-elevation myocardial infarction (STEMI). The study included 77 patients where we measured serum vitamin D levels, thrombus degree, and other relevant factors.
Our findings revealed that a concerning 79.22% of participants showed vitamin D deficiency, with those having milder thrombus loads possessing significantly higher vitamin D levels compared to those with severe thrombus loads. Moreover, as we assessed the severity of coronary artery condition, we noted that patients with higher thrombus burden also had markedly greater scores of atherosclerosis.
Importantly, we found clear negative correlations between vitamin D levels and measures of thrombus burden. Lower vitamin D levels aligned with higher TIMI frame counts—meaning more extensive vascular obstruction—suggesting that vitamin D might play a role in blood clot formation.
Overall, we determined that low 25(OH)D3 levels could be an independent predictor of high coronary artery thrombus load in STEMI patients. These findings highlight the potential significance of monitoring and perhaps addressing vitamin D levels in this vulnerable group.
Our findings revealed that a concerning 79.22% of participants showed vitamin D deficiency, with those having milder thrombus loads possessing significantly higher vitamin D levels compared to those with severe thrombus loads. Moreover, as we assessed the severity of coronary artery condition, we noted that patients with higher thrombus burden also had markedly greater scores of atherosclerosis.
Importantly, we found clear negative correlations between vitamin D levels and measures of thrombus burden. Lower vitamin D levels aligned with higher TIMI frame counts—meaning more extensive vascular obstruction—suggesting that vitamin D might play a role in blood clot formation.
Overall, we determined that low 25(OH)D3 levels could be an independent predictor of high coronary artery thrombus load in STEMI patients. These findings highlight the potential significance of monitoring and perhaps addressing vitamin D levels in this vulnerable group.
Read More
4
We investigated the effects of high-dose vitamin D3 on blood clotting parameters in patients suffering from venous thromboembolism (VTE), specifically looking at levels of P-selectin and high-sensitive C-reactive protein (hs-CRP). The study involved 60 participants who were diagnosed with acute deep vein thrombosis or pulmonary embolism.
These patients were randomly divided into two groups—one receiving a single dose of 300,000 IU of vitamin D3 and the other group serving as a control. Over the course of four weeks, we measured the levels of vitamin D, P-selectin, and hs-CRP to assess any changes resulting from the treatment.
While we noticed a significant decline in both P-selectin and hs-CRP in those who received vitamin D3, the overall reductions were not substantial enough to indicate a major benefit. In comparison, only hs-CRP decreased significantly in the control group. Therefore, we conclude that, based on our findings, high-dose vitamin D3 does not show a strong impact on lowering P-selectin levels or hs-CRP in patients with VTE.
These patients were randomly divided into two groups—one receiving a single dose of 300,000 IU of vitamin D3 and the other group serving as a control. Over the course of four weeks, we measured the levels of vitamin D, P-selectin, and hs-CRP to assess any changes resulting from the treatment.
While we noticed a significant decline in both P-selectin and hs-CRP in those who received vitamin D3, the overall reductions were not substantial enough to indicate a major benefit. In comparison, only hs-CRP decreased significantly in the control group. Therefore, we conclude that, based on our findings, high-dose vitamin D3 does not show a strong impact on lowering P-selectin levels or hs-CRP in patients with VTE.
Read More
9
We explored the effects of vitamin D3 on blood clot formation in mice lacking the klotho protein, which plays a role in regulating vitamin D3 levels. In our analysis, we focused on how klotho deficiency impacts platelet function and calcium signaling, pivotal mechanisms involved in clotting.
Our findings revealed that klotho-deficient platelets exhibited significantly reduced responses to activation, indicating that they might not form clots effectively. Specifically, we observed that calcium signaling pathways, essential for platelet activation and aggregation, were notably inhibited in these mice. The investigation utilized multiple methods, including measuring calcium levels and evaluating platelet function through various biochemical and cellular techniques.
Interestingly, when klotho-deficient mice were given a low-vitamin D diet, we discovered that their platelet function improved, suggesting a direct link between vitamin D3 levels and platelet activity. The reduced activity was associated with decreased expression of critical signaling proteins involved in calcium entry, which vitamin D3 helps regulate. Overall, our study presents evidence that vitamin D3 deficiency due to klotho absence may hinder proper blood clotting mechanisms.
Our findings revealed that klotho-deficient platelets exhibited significantly reduced responses to activation, indicating that they might not form clots effectively. Specifically, we observed that calcium signaling pathways, essential for platelet activation and aggregation, were notably inhibited in these mice. The investigation utilized multiple methods, including measuring calcium levels and evaluating platelet function through various biochemical and cellular techniques.
Interestingly, when klotho-deficient mice were given a low-vitamin D diet, we discovered that their platelet function improved, suggesting a direct link between vitamin D3 levels and platelet activity. The reduced activity was associated with decreased expression of critical signaling proteins involved in calcium entry, which vitamin D3 helps regulate. Overall, our study presents evidence that vitamin D3 deficiency due to klotho absence may hinder proper blood clotting mechanisms.
Read More
Most Useful Reviews
9
Maintains blood quality
13 people found this helpful
All tests are perfect. I started taking it in the first trimester of pregnancy, and I’m now 27 weeks along. I bought 2-3 cans and continue taking it. I experienced some issues like belching but no nausea. The small capsules are easy to swallow. It's essential to store them in the fridge, as heat can make them smell like fish. Omega is known to help maintain normal blood quality, preventing blood clots. Monthly tests show my platelets and erythrocytes are normal. I highly recommend it!
Read More
7.5
Pregnancy support discussed
9 people found this helpful
Following two miscarriages, my midwife suggested Folate and Baby Aspirin for my next pregnancy. As directed, I got my progesterone checked. The baby aspirin is intended to help prevent any blood clots. I find this routine easy and would recommend it to any expecting mothers, especially those with complications like mine.
Read More
7.5
Improves blood circulation
After pregnancy, I had an issue with a blood clot on my leg, so I bought this for better blood circulation. Interestingly, after taking it, the problem seems to have improved.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 28 Researches
7.1
- All Researches
9
We explored the effects of vitamin D3 on blood clot formation in mice lacking the klotho protein, which plays a role in regulating vitamin D3 levels. In our analysis, we focused on how klotho deficiency impacts platelet function and calcium signaling, pivotal mechanisms involved in clotting.
Our findings revealed that klotho-deficient platelets exhibited significantly reduced responses to activation, indicating that they might not form clots effectively. Specifically, we observed that calcium signaling pathways, essential for platelet activation and aggregation, were notably inhibited in these mice. The investigation utilized multiple methods, including measuring calcium levels and evaluating platelet function through various biochemical and cellular techniques.
Interestingly, when klotho-deficient mice were given a low-vitamin D diet, we discovered that their platelet function improved, suggesting a direct link between vitamin D3 levels and platelet activity. The reduced activity was associated with decreased expression of critical signaling proteins involved in calcium entry, which vitamin D3 helps regulate. Overall, our study presents evidence that vitamin D3 deficiency due to klotho absence may hinder proper blood clotting mechanisms.
Our findings revealed that klotho-deficient platelets exhibited significantly reduced responses to activation, indicating that they might not form clots effectively. Specifically, we observed that calcium signaling pathways, essential for platelet activation and aggregation, were notably inhibited in these mice. The investigation utilized multiple methods, including measuring calcium levels and evaluating platelet function through various biochemical and cellular techniques.
Interestingly, when klotho-deficient mice were given a low-vitamin D diet, we discovered that their platelet function improved, suggesting a direct link between vitamin D3 levels and platelet activity. The reduced activity was associated with decreased expression of critical signaling proteins involved in calcium entry, which vitamin D3 helps regulate. Overall, our study presents evidence that vitamin D3 deficiency due to klotho absence may hinder proper blood clotting mechanisms.
Read More
9
We evaluated the potential of vitamin D3, specifically calcitriol, in combination with other medications to prevent deep vein thrombosis (VTE) in renal transplant recipients (RTR). Focusing on how these treatments might influence the occurrence of blood clots, we followed a group of 769 RTRs over several months post-transplant.
Our findings revealed that 96 of these recipients experienced a first episode of VTE. We noticed a significant difference in rates of blood clots among those who received calcitriol alongside angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs). In fact, recipients on the combination therapy had a markedly lower rate of VTE, showing a promising 60% reduction in risk.
However, it is important to note that the isolated effect of vitamin D3 without other treatments wasn't fully determined in this study. While calcitriol showed favorable outcomes when used with blood pressure medications, further research could help clarify its individual impact on clot prevention. Overall, this research highlights the importance of collaborative strategies in managing thrombotic complications for transplant patients.
Our findings revealed that 96 of these recipients experienced a first episode of VTE. We noticed a significant difference in rates of blood clots among those who received calcitriol alongside angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs). In fact, recipients on the combination therapy had a markedly lower rate of VTE, showing a promising 60% reduction in risk.
However, it is important to note that the isolated effect of vitamin D3 without other treatments wasn't fully determined in this study. While calcitriol showed favorable outcomes when used with blood pressure medications, further research could help clarify its individual impact on clot prevention. Overall, this research highlights the importance of collaborative strategies in managing thrombotic complications for transplant patients.
Read More
9
Eicosapentaenoic acid influences clotting
We explored how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, influences blood clotting processes. The interest in EPA grew substantially after the 1970s when researchers Dyerberg and Bang noted that Greenland Eskimos had lower rates of coronary disease linked to their diet rich in marine lipids.
Their findings suggested that the higher levels of EPA led to reduced platelet aggregation, which essentially means that the blood clots less easily. This anti-clotting effect is significant since blood clots can lead to serious health issues like heart attacks and strokes.
Although studies have shown these promising effects, it’s crucial to note that much of the initial acclaim came from dietary observations rather than controlled clinical trials. This means that while we can relate high EPA intake to lower health risks in specific populations, we still need more rigorous studies to fully understand the impact of EPA on blood clotting across diverse groups.
Their findings suggested that the higher levels of EPA led to reduced platelet aggregation, which essentially means that the blood clots less easily. This anti-clotting effect is significant since blood clots can lead to serious health issues like heart attacks and strokes.
Although studies have shown these promising effects, it’s crucial to note that much of the initial acclaim came from dietary observations rather than controlled clinical trials. This means that while we can relate high EPA intake to lower health risks in specific populations, we still need more rigorous studies to fully understand the impact of EPA on blood clotting across diverse groups.
Read More
9
We explored the effects of eicosapentaenoic acid (EPA), particularly in the context of acute coronary syndrome (ACS), on blood clotting. The study highlighted how different subclasses of high-density lipoprotein (HDL), particularly HDL2 from ACS patients, interact with platelets during clot formation.
It became clear that HDL2 from ACS patients exhibited a stronger ability to inhibit platelet aggregation compared to HDL from healthy individuals. This ability to reduce clot formation is linked to the presence of specific oxidized polyunsaturated fatty acids in the HDL2 particles.
We observed an inverse relationship between several oxidized fatty acids, such as 18-hydroxyeicosapentaenoic acid (18-HEPE) and others, and platelet aggregation. This means that higher levels of these oxidized fats were associated with less platelet activation and clotting, pointing to their potential role in enhancing the antithrombotic properties of HDL2 in ACS patients.
Overall, the findings suggest that EPA and its oxidized metabolites could play a key role in modifying HDL properties, thereby offering some protection against blood clots in individuals with ACS.
It became clear that HDL2 from ACS patients exhibited a stronger ability to inhibit platelet aggregation compared to HDL from healthy individuals. This ability to reduce clot formation is linked to the presence of specific oxidized polyunsaturated fatty acids in the HDL2 particles.
We observed an inverse relationship between several oxidized fatty acids, such as 18-hydroxyeicosapentaenoic acid (18-HEPE) and others, and platelet aggregation. This means that higher levels of these oxidized fats were associated with less platelet activation and clotting, pointing to their potential role in enhancing the antithrombotic properties of HDL2 in ACS patients.
Overall, the findings suggest that EPA and its oxidized metabolites could play a key role in modifying HDL properties, thereby offering some protection against blood clots in individuals with ACS.
Read More
9
Fish oil may reduce clotting risk
We explored the effects of eicosapentaenoic acid (EPA) found in fish oil supplements on the risk of blood clotting in patients with suspected coronary artery disease who weren’t taking lipid-lowering medications. The study included 600 consecutive patients, and we compared those taking fish oil to those who weren’t.
Our findings showed that fish oil supplementation was associated with beneficial changes in several cholesterol levels, particularly lower levels of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) cholesterol. This aligns with evidence that EPA could play a role in heart health.
Notably, patients who took fish oil demonstrated reduced platelet aggregation and lower levels of urinary thromboxane B2, a marker associated with blood clot formation. This suggests that fish oil could potentially help in lowering atherothrombotic risk, especially for those not on other cholesterol-lowering treatments.
While the results are promising, further studies are warranted to confirm these findings and better understand the independent effects of EPA on blood clotting.
Our findings showed that fish oil supplementation was associated with beneficial changes in several cholesterol levels, particularly lower levels of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) cholesterol. This aligns with evidence that EPA could play a role in heart health.
Notably, patients who took fish oil demonstrated reduced platelet aggregation and lower levels of urinary thromboxane B2, a marker associated with blood clot formation. This suggests that fish oil could potentially help in lowering atherothrombotic risk, especially for those not on other cholesterol-lowering treatments.
While the results are promising, further studies are warranted to confirm these findings and better understand the independent effects of EPA on blood clotting.
Read More
User Reviews
USERS' SCORE
Good
Based on 4 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
9
Maintains blood quality
13 people found this helpful
All tests are perfect. I started taking it in the first trimester of pregnancy, and I’m now 27 weeks along. I bought 2-3 cans and continue taking it. I experienced some issues like belching but no nausea. The small capsules are easy to swallow. It's essential to store them in the fridge, as heat can make them smell like fish. Omega is known to help maintain normal blood quality, preventing blood clots. Monthly tests show my platelets and erythrocytes are normal. I highly recommend it!
Read More
7.5
Pregnancy support discussed
9 people found this helpful
Following two miscarriages, my midwife suggested Folate and Baby Aspirin for my next pregnancy. As directed, I got my progesterone checked. The baby aspirin is intended to help prevent any blood clots. I find this routine easy and would recommend it to any expecting mothers, especially those with complications like mine.
Read More
7.5
Improves blood circulation
After pregnancy, I had an issue with a blood clot on my leg, so I bought this for better blood circulation. Interestingly, after taking it, the problem seems to have improved.
Read More
7.5
Supports normal indicators
Omega is considered beneficial for thinning blood. Many say it’s particularly useful in the second and third trimesters, but I recommend starting from the first, especially if there is a risk of blood clots. My first pregnancy required clexane, but I managed my second without it, focusing on hydration and this product due to its purification level. I can’t speak to the effects, but my health indicators remain normal.
Read More
Frequently Asked Questions
7.5
Improves blood circulation
After pregnancy, I had an issue with a blood clot on my leg, so I bought this for better blood circulation. Interestingly, after taking it, the problem seems to have improved.
7.5
Supports normal indicators
Omega is considered beneficial for thinning blood. Many say it’s particularly useful in the second and third trimesters, but I recommend starting from the first, especially if there is a risk of blood clots. My first pregnancy required clexane, but I managed my second without it, focusing on hydration and this product due to its purification level. I can’t speak to the effects, but my health indicators remain normal.
9
Maintains blood quality
13 people found this helpful
All tests are perfect. I started taking it in the first trimester of pregnancy, and I’m now 27 weeks along. I bought 2-3 cans and continue taking it. I experienced some issues like belching but no nausea. The small capsules are easy to swallow. It's essential to store them in the fridge, as heat can make them smell like fish. Omega is known to help maintain normal blood quality, preventing blood clots. Monthly tests show my platelets and erythrocytes are normal. I highly recommend it!
8
We focused on how 1,25-Dihydroxyvitamin D3, or vitamin D3, affects platelet aggregation, particularly in response to the SARS-CoV-2 spike protein. Individuals with COVID-19 often experience heightened blood clotting, which can lead to serious complications. Our study aimed to uncover the mechanisms behind vitamin D3’s potential benefits in reducing this risk.
Through our experiments, we discovered that vitamin D3 helped reduce platelet aggregation triggered by the spike protein. We noticed that it inhibited certain signaling pathways inside platelets, thereby curbing their ability to clump together. Even when the spike protein was introduced, vitamin D3 managed to lessen the platelet response significantly.
Interestingly, our findings suggest that vitamin D3 works by modulating a specific integrin signaling pathway, known as integrin αIIbβ3 outside-in signaling. We observed that this process involved key proteins that play a role in platelet function. Combining vitamin D3 with a Src family kinase inhibitor showed no added benefits, indicating that vitamin D3's effects might be closely tied to these signaling pathways.
Overall, our study indicates that vitamin D3 has a beneficial role in mitigating the heightened platelet activity associated with the spike protein, offering insights into its potential use as a treatment option during COVID-19.
Through our experiments, we discovered that vitamin D3 helped reduce platelet aggregation triggered by the spike protein. We noticed that it inhibited certain signaling pathways inside platelets, thereby curbing their ability to clump together. Even when the spike protein was introduced, vitamin D3 managed to lessen the platelet response significantly.
Interestingly, our findings suggest that vitamin D3 works by modulating a specific integrin signaling pathway, known as integrin αIIbβ3 outside-in signaling. We observed that this process involved key proteins that play a role in platelet function. Combining vitamin D3 with a Src family kinase inhibitor showed no added benefits, indicating that vitamin D3's effects might be closely tied to these signaling pathways.
Overall, our study indicates that vitamin D3 has a beneficial role in mitigating the heightened platelet activity associated with the spike protein, offering insights into its potential use as a treatment option during COVID-19.
8
We explored the connection between vitamin D levels and coronary thrombus load in patients who experienced ST-elevation myocardial infarction (STEMI). The study included 77 patients where we measured serum vitamin D levels, thrombus degree, and other relevant factors.
Our findings revealed that a concerning 79.22% of participants showed vitamin D deficiency, with those having milder thrombus loads possessing significantly higher vitamin D levels compared to those with severe thrombus loads. Moreover, as we assessed the severity of coronary artery condition, we noted that patients with higher thrombus burden also had markedly greater scores of atherosclerosis.
Importantly, we found clear negative correlations between vitamin D levels and measures of thrombus burden. Lower vitamin D levels aligned with higher TIMI frame counts—meaning more extensive vascular obstruction—suggesting that vitamin D might play a role in blood clot formation.
Overall, we determined that low 25(OH)D3 levels could be an independent predictor of high coronary artery thrombus load in STEMI patients. These findings highlight the potential significance of monitoring and perhaps addressing vitamin D levels in this vulnerable group.
Our findings revealed that a concerning 79.22% of participants showed vitamin D deficiency, with those having milder thrombus loads possessing significantly higher vitamin D levels compared to those with severe thrombus loads. Moreover, as we assessed the severity of coronary artery condition, we noted that patients with higher thrombus burden also had markedly greater scores of atherosclerosis.
Importantly, we found clear negative correlations between vitamin D levels and measures of thrombus burden. Lower vitamin D levels aligned with higher TIMI frame counts—meaning more extensive vascular obstruction—suggesting that vitamin D might play a role in blood clot formation.
Overall, we determined that low 25(OH)D3 levels could be an independent predictor of high coronary artery thrombus load in STEMI patients. These findings highlight the potential significance of monitoring and perhaps addressing vitamin D levels in this vulnerable group.
2
Vitamin D treatment shows no benefit
In our exploration of how vitamin D might affect blood clotting, we conducted a pilot randomized clinical trial involving 40 patients diagnosed with either deep vein thrombosis or pulmonary embolism. These individuals were vitamin D deficient, which is already known to contribute to the development of blood clots.
We divided the patients into two groups: one received a high dose of vitamin D—50,000 IU weekly for eight weeks followed by less frequent doses—while the control group did not receive any vitamin D. After one and three months, we measured levels of two key biomarkers related to blood clotting: P-selectin and hs-CRP.
We discovered that there was no significant decrease in either biomarker in both groups over the study period. This suggests that treating vitamin D deficiency doesn’t meaningfully impact these specific markers of thrombosis in patients with clotting issues.
However, we did find something interesting. Those who received vitamin D treatment appeared to manage their anticoagulant therapy with warfarin more effectively, using lower doses of the medication. While our initial hypothesis about vitamin D’s direct effect on blood clot markers didn’t hold, this potential interaction with warfarin is intriguing and warrants further investigation in larger studies to better understand the relationship between vitamin D and blood clotting.
We divided the patients into two groups: one received a high dose of vitamin D—50,000 IU weekly for eight weeks followed by less frequent doses—while the control group did not receive any vitamin D. After one and three months, we measured levels of two key biomarkers related to blood clotting: P-selectin and hs-CRP.
We discovered that there was no significant decrease in either biomarker in both groups over the study period. This suggests that treating vitamin D deficiency doesn’t meaningfully impact these specific markers of thrombosis in patients with clotting issues.
However, we did find something interesting. Those who received vitamin D treatment appeared to manage their anticoagulant therapy with warfarin more effectively, using lower doses of the medication. While our initial hypothesis about vitamin D’s direct effect on blood clot markers didn’t hold, this potential interaction with warfarin is intriguing and warrants further investigation in larger studies to better understand the relationship between vitamin D and blood clotting.
4
Calcium and vitamin D3 impact on VTE
We aimed to understand how vitamin D3, when combined with calcium, might affect the risk of developing blood clots, also known as venous thromboembolism (VTE). In a notable study involving over 36,000 postmenopausal women aged between 50 to 79, participants were randomly assigned to receive either daily supplements of 1,000 mg of calcium and 400 IU of vitamin D3 or a placebo. This rigorous double-blind, placebo-controlled design lasted an average of seven years, ensuring that neither the participants nor the researchers knew who was receiving the active treatment.
Our analysis looked closely at the rates of VTE between those taking the supplements and those on the placebo. We found that there was no significant difference in the overall incidence of VTE between the two groups—320 events in the supplement group versus 348 in the placebo group. This translates to a hazard ratio of 0.92, suggesting that the combined supplementation did not lower the risk of blood clots for these generally healthy women.
Interestingly, while the overall risk didn’t change, we observed a noticeable reduction in the risk of idiopathic VTE (where there’s no clear cause) among women who took calcium and vitamin D3, with 40 events compared to 65 in the placebo group. This finding may call for deeper investigation, as it hints at a potential benefit that could be worth exploring further.
To sum up, regular supplementation with calcium and vitamin D3 does not seem to reduce the overall risk of blood clots in postmenopausal women. However, our observation of a lower risk for idiopathic blood clots in the treatment group offers a glimmer of hope for future studies on this topic.
Our analysis looked closely at the rates of VTE between those taking the supplements and those on the placebo. We found that there was no significant difference in the overall incidence of VTE between the two groups—320 events in the supplement group versus 348 in the placebo group. This translates to a hazard ratio of 0.92, suggesting that the combined supplementation did not lower the risk of blood clots for these generally healthy women.
Interestingly, while the overall risk didn’t change, we observed a noticeable reduction in the risk of idiopathic VTE (where there’s no clear cause) among women who took calcium and vitamin D3, with 40 events compared to 65 in the placebo group. This finding may call for deeper investigation, as it hints at a potential benefit that could be worth exploring further.
To sum up, regular supplementation with calcium and vitamin D3 does not seem to reduce the overall risk of blood clots in postmenopausal women. However, our observation of a lower risk for idiopathic blood clots in the treatment group offers a glimmer of hope for future studies on this topic.
References
- Wang R, Tian Z, Wang C, Zhang B, Zhu M, et al. 1,25-Dihydroxyvitamin D3 attenuates platelet aggregation potentiated by SARS-CoV-2 spike protein via inhibiting integrin αIIbβ3 outside-in signaling. Cell Biochem Funct. 2024;42:e4039. 10.1002/cbf.4039
- Uguz B, Oztas S, Zengin I, Topal D, Tiryakioglu SK, et al. Relationship between vitamin D deficiency and thrombus load in patients with ST-elevation myocardial infarction. Eur Rev Med Pharmacol Sci. 2022;26:7015. 10.26355/eurrev_202210_29885
- Hejazi ME, Modarresi-Ghazani F, Hamishehkar H, Mesgari-Abbasi M, Dousti S, et al. The Effect of Treatment of Vitamin D Deficiency on the Level of P-Selectin and hs-CRP in Patients With Thromboembolism: A Pilot Randomized Clinical Trial. J Clin Pharmacol. 2017;57:40. 10.1002/jcph.774
- Blondon M, Rodabough RJ, Budrys N, Johnson KC, Berger JS, et al. The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial. Thromb Haemost. 2015;113:999. 10.1160/TH14-05-0478
- Gholami K, Talasaz AH, Entezari-Maleki T, Salarifar M, Hadjibabaie M, et al. The Effect of High-Dose Vitamin D3 on Soluble P-Selectin and hs-CRP Level in Patients With Venous Thromboembolism: A Randomized Clinical Trial. Clin Appl Thromb Hemost. 2016;22:483. 10.1177/1076029614568715
- Borst O, Münzer P, Schmid E, Schmidt EM, Russo A, et al. 1,25(OH)2 vitamin D3-dependent inhibition of platelet Ca2+ signaling and thrombus formation in klotho-deficient mice. FASEB J. 2014;28:2108. 10.1096/fj.13-239277
- Moscarelli L, Zanazzi M, Bertoni E, Caroti L, Rosso G, et al. Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients. Clin Nephrol. 2011;75:440.
- Jorde R, Sneve M, Torjesen P, Figenschau Y, Hansen JB. Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. Thromb Res. 2010;125:e210. 10.1016/j.thromres.2009.12.011
- Wu-Wong JR. Are vitamin D receptor activators useful for the treatment of thrombosis?. Curr Opin Investig Drugs. 2009;10:919.
- Reiner MF, Bertschi DA, Werlen L, Wiencierz A, Aeschbacher S, et al. Omega-3 Fatty Acids and Markers of Thrombosis in Patients with Atrial Fibrillation. Nutrients. 2024;16. 10.3390/nu16020178
- Lu LW, Quek SY, Lu SP, Chen JH. Potential Benefits of Omega-3 Polyunsaturated Fatty Acids (N3PUFAs) on Cardiovascular Health Associated with COVID-19: An Update for 2023. Metabolites. 2023;13. 10.3390/metabo13050630
- Yuan S, Li X, Morange PE, Bruzelius M, Larsson SC. Plasma Phospholipid Fatty Acids and Risk of Venous Thromboembolism: Mendelian Randomization Investigation. Nutrients. 2022;14. 10.3390/nu14163354
- Nakao S, Ishihara T, Tsujimura T, Iida O, Hata Y, et al. Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome. J Cardiol. 2022;79:391. 10.1016/j.jjcc.2021.10.005
- Djuricic I, Calder PC. Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021. Nutrients. 2021;13. 10.3390/nu13072421
- Gaertner S, Auger C, Farooq MA, Pollet B, Khemais-Benkhiat S, et al. Oral Intake of EPA:DHA 6:1 by Middle-Aged Rats for One Week Improves Age-Related Endothelial Dysfunction in Both the Femoral Artery and Vein: Role of Cyclooxygenases. Int J Mol Sci. 2020;21. 10.3390/ijms21030920
- Akintoye E, Sethi P, Harris WS, Thompson PA, Marchioli R, et al. Fish Oil and Perioperative Bleeding. Circ Cardiovasc Qual Outcomes. 2018;11:e004584. 10.1161/CIRCOUTCOMES.118.004584
- Spector AA, Kim HY. Emergence of omega-3 fatty acids in biomedical research. Prostaglandins Leukot Essent Fatty Acids. 2019;140:47. 10.1016/j.plefa.2018.11.017
- Garcia C, Montée N, Faccini J, Series J, Meilhac O, et al. Acute coronary syndrome remodels the antiplatelet aggregation properties of HDL particle subclasses. J Thromb Haemost. 2018;16:933. 10.1111/jth.14003
- Adili R, Voigt EM, Bormann JL, Foss KN, Hurley LJ, et al. In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi. Platelets. 2019;30:271. 10.1080/09537104.2017.1420154
- Saber H, Yakoob MY, Shi P, Longstreth WT, Lemaitre RN, et al. Omega-3 Fatty Acids and Incident Ischemic Stroke and Its Atherothrombotic and Cardioembolic Subtypes in 3 US Cohorts. Stroke. 2017;48:2678. 10.1161/STROKEAHA.117.018235
- Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, et al. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016;30:2792. 10.1096/fj.201500155R
- Franzese CJ, Bliden KP, Gesheff MG, Pandya S, Guyer KE, et al. Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. Am J Cardiol. 2015;115:1204. 10.1016/j.amjcard.2015.02.002
- Sofi F, Giorgi G, Cesari F, Gori AM, Mannini L, et al. The atherosclerotic risk profile is affected differently by fish flesh with a similar EPA and DHA content but different n-6/n-3 ratio. Asia Pac J Clin Nutr. 2013;22:32. 10.6133/apjcn.2013.22.1.12
- McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost. 2013;39:25. 10.1055/s-0032-1333309
- Yamaguchi A, Stanger L, Freedman CJ, Standley M, Hoang T, et al. DHA 12-LOX-derived oxylipins regulate platelet activation and thrombus formation through a PKA-dependent signaling pathway. J Thromb Haemost. 2021;19:839. 10.1111/jth.15184
- Takagaki S, Suzuki M, Suzuki E, Hasumi K. Unsaturated fatty acids enhance the fibrinolytic activity of subtilisin NAT (nattokinase). J Food Biochem. 2020;44:e13326. 10.1111/jfbc.13326
- Perry SC, Kalyanaraman C, Tourdot BE, Conrad WS, Akinkugbe O, et al. 15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15-lipoxygenase-2 in biosynthesis of resolvin D5. J Lipid Res. 2020;61:1087. 10.1194/jlr.RA120000777
- Unsworth AJ, Flora GD, Sasikumar P, Bye AP, Sage T, et al. RXR Ligands Negatively Regulate Thrombosis and Hemostasis. Arterioscler Thromb Vasc Biol. 2017;37:812. 10.1161/ATVBAHA.117.309207
